Sinobiopharma Inc
Sinobiopharma is a fully integrated and high growth company engaged in the R&D, manufacture and distribution of biopharmaceutical products.
See more information about Sinobiopharma Inc
Sinobiopharma appoints Chief Financial Officer and Director to the Board
Sinobiopharma, Inc. (OTC:SNBP) is pleased to announce that it has appointed Mu Xinjie as the new Chief Financial Officer and as a director on the Board.
President and CEO of Sinobiopharma Dr. Huang Lequn resigned as the Chief Financial Officer in order to make room for the appointment of Mr. Mu.
Mr. Mu has more than twelve years experience in the financial field. Most recently, Mr. Mu has been an independent consultant working for China based US public companies. Prior to that, he was a Chief Financial Officer at Jingwei International Limited (OTC:JNGW.OB). Prior to that, he served as a senior accountant at Geller and Company in New York City.
Mr. Mu is also a Director of China Infrastructure Investment Corporation (NASDAQ: CIIC) since March 2008. Fluent in Mandarin and English, Mr. Mu holds a Bachelor of Science degree from Hebei University of Science and Technology, and a Master of Business Administration from Baruch College at the City University of New York.
.
Separately, the Company announces that Mr. Martin Shen resigned as director of the Board for personal reasons.
''On behalf of the Board of Directors and Sinobiopharma, I want to personally thank Mr. Shen for his contributions to the Company and wish him well,'' said Dr. Lequn Huang, President and CEO of Sinobiopharma.
Other Sinobiopharma Inc news
- Sinobiopharma signs distribution contracts for flagship product
2010-07-06 - Sinobiopharma gains approval for the use of Gabexate Mesylate as pharmaceutical raw material
2009-10-09 - Emissary starts coverage of Sinobiopharma with Buy target of $1.25
2009-09-22
